Short-Term Efficacy and Safety of Phacoemulsification Associated With iStent Inject W in Patients With Controlled Open Angle Glaucoma.
Louanchi Yanis, Brasnu Emmanuelle, Hamard Pascale, Aragno Vittoria, Baudouin Christophe, Labbé Antoine
AI Summary
Phacoemulsification with iStent inject W effectively lowered IOP and medication burden in controlled open-angle glaucoma patients, offering a safe option for concurrent cataract and glaucoma management.
Abstract
Précis: The iStent inject W implanted during phacoemulsification effectively reduces IOP.
Purpose
The purpose of this study was to evaluate the efficacy and safety of iStent inject W combined with phacoemulsification in patients with controlled open angle glaucoma undergoing cataract surgery.
Patients and methods: We conducted a retrospective, bicentric study of patients with controlled chronic open angle glaucoma who underwent phacoemulsification combined with the injection of 2 iStent inject Ws. Patient characteristics, including intraocular pressure (IOP) and the number of glaucoma medications, were evaluated preoperatively and 1 week, 1 month, and 6 months postoperatively. The primary end point was IOP reduction, and the secondary end point was the reduction in the number of glaucoma medications.
Results
In this study, 85 eyes were included. The majority of patients had primary open angle glaucoma (85% of eyes). Preoperative mean IOP was 16.1±2.0 mm Hg with a mean of 2.3±0.5 glaucoma medications. At 1 week postoperatively, the mean IOP was 16.7±3.1 mm Hg with a mean of 2.0±0.7 hypotensive medications. At 1 and 6 months, the mean IOP was 14.2±2.1 and 13.0±1.5 mm Hg, with a mean of 2.0±0.6 and 1.8±0.5 glaucoma medications, respectively. The percentage IOP reduction at 1 and 6 months was 11.6% ( P =0.001) and 19.3% ( P <0.0001), respectively. Regarding glaucoma medications, at 1 and 6 months, the reduction in the number of medications was 12.9% ( P =0.025) and 22.4% ( P =0.003), respectively. The most frequent significant postoperative adverse events were corneal edema in 7%, IOP spikes in 6%, and hyphema in 6% of eyes, which resolved spontaneously.
Conclusions
The iStent inject W implanted during phacoemulsification effectively reduces IOP and the number of glaucoma medications needed at 6 months of follow-up, with a favorable safety profile in patients with controlled open angle glaucoma.
MeSH Terms
Shields Classification
Key Concepts4
A retrospective, bicentric study of 85 eyes from patients with controlled chronic open angle glaucoma who underwent phacoemulsification combined with the injection of 2 iStent inject Ws found that the iStent inject W effectively reduces IOP.
In a retrospective, bicentric study of 85 eyes with controlled chronic open angle glaucoma, phacoemulsification combined with the injection of 2 iStent inject Ws resulted in an IOP reduction of 11.6% (P=0.001) at 1 month and 19.3% (P<0.0001) at 6 months postoperatively.
A retrospective, bicentric study of 85 eyes with controlled chronic open angle glaucoma found that phacoemulsification combined with the injection of 2 iStent inject Ws reduced the number of glaucoma medications by 12.9% (P=0.025) at 1 month and 22.4% (P=0.003) at 6 months postoperatively.
The most frequent significant postoperative adverse events after phacoemulsification combined with the injection of 2 iStent inject Ws in 85 eyes with controlled chronic open angle glaucoma were corneal edema in 7%, IOP spikes in 6%, and hyphema in 6% of eyes, all of which resolved spontaneously.
Related Articles5
Combined Phacoemulsification and Hydrus Microstent Implantation in Asian Eyes With Moderate-to-Severe Normal Tension Glaucoma-12-Month Outcomes.
Case SeriesIOP-lowering and drug-sparing effects of trabectome surgery with or without cyclodialysis ab interno.
Case Series36-Month Multi-Centre Outcomes of Combined Phacoemulsification and Hydrus Microstent Implantation in Eyes with Normal Tension Glaucoma.
Cohort StudyManchester iStent study: early results from a prospective UK case series.
Case SeriesPhacoemulsification versus phacoemulsification with micro-bypass stent implantation in primary open-angle glaucoma: randomized double-masked clinical trial.
Randomized Controlled TrialIs this article assigned to the wrong chapter(s)? Let us know.